Solid dosage CDMO invests in spray drying

New equipment allows Genvion to take customers from development through to commercial manufacture.

The Canadian CDMO, which specialises in cytotoxic and highly potent solid dosage forms, has added new capabilities bringing on-line spray dryers and Wurster coaters following the successful installation and validation of the advanced manufacturing equipment at its new, state-of-the-art 80,000 sq. ft facility.

The new equipment gives the CDMO spray drying capabilities in both R&D and commercial manufacturing.

Genvion vice president, Tony Cocci said: “Customer demand for GMP spray drying is increasing because of the need to support poorly soluble drugs. This latest investment diversifies Genvion’s capability to address these demands and broadens our manufacturing services, whilst also boosting our existing high containment and cytotoxic niche expertise.

“Market response to the investment in our capabilities has been very encouraging with both existing and new customers taking advantage of our wider portfolio of services, particularly our ability to take customers from development through to commercial manufacture.”

The substantial investment, expected to be close to $1.5 million when taking into account both the spray drying and Wurster equipment, is part of Genvion’s ongoing plans to expand its GMP manufacturing capabilities at its facility in Winnipeg, Canada and comes in direct response to customer demand for spray drying and drug layering from Big Pharma through to small specialty firms.

Cocci added: “This latest investment forms part of our ongoing commitment to improving our customer offer with new machinery and providing solutions for industry-wide issues such as poor drug solubility. We’re confident this new service will further strengthen our client relationships and allow us to continue our planned business growth.”